{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:10:54Z","timestamp":1793988654269,"version":"4.8.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Synaptic Neurosci."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is an extrapyramidal disorder characterized by neuronal degeneration in several regions of the peripheral and central nervous systems. It is the second most frequent neurodegenerative disease after Alzheimer\u2019s. It has become a major health problem, affecting 1% of the world population over 60 years old and 3% of people beyond 80 years. The main histological findings are intracellular Lewy bodies composed of misfolded \u03b1-synuclein protein aggregates and loss of dopaminergic neurons in the central nervous system. Neuroinflammation, apoptosis, mitochondrial dysfunction, altered calcium homeostasis, abnormal protein degradation, and synaptic pathobiology have been put forward as mechanisms leading to cell death, \u03b1-synuclein deposition, or both. A progressive loss of dopaminergic neurons in the substantia nigra late in the neurodegeneration leads to developing motor symptoms like bradykinesia, tremor, and rigidity. The renin\u2013angiotensin system (RAS), which is involved in regulating blood pressure and body fluid balance, also plays other important functions in the brain. The RAS is involved in the autocrine and paracrine regulation of the nigrostriatal dopaminergic synapses. Dopamine depletion, as in PD, increases angiotensin II expression, which stimulates or inhibits dopamine synthesis and is released via AT1 or AT2 receptors. Furthermore, angiotensin II AT1 receptors inhibit D1 receptor activation allosterically. Therefore, the RAS may have an important modulating role in the flow of information from the brain cortex to the basal ganglia. High angiotensin II levels might even aggravate neurodegeneration, activating the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, which leads to increased reactive oxygen species production.<\/jats:p>","DOI":"10.3389\/fnsyn.2021.638519","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T09:42:17Z","timestamp":1619084537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["The Renin\u2013Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene"],"prefix":"10.3389","volume":"13","author":[{"given":"Tamara","family":"Kobiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Otero-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenson","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Udovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Men\u00e9ndez-Maissonave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Capani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"P\u00e9rez-Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.peptides.2012.09.016","article-title":"Subcellular characteristics of functional intracellular renin-angiotensin systems.","volume":"38","author":"Abadir","year":"2012","journal-title":"Peptides"},{"key":"B2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ana.410320306","article-title":"Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.","volume":"32","author":"Allen","year":"1992","journal-title":"Ann. Neurol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104612","article-title":"Neuroprotective potential of chrysin in Parkinson\u2019s disease: Molecular mechanisms and clinical implications.","volume":"136","author":"Angelopoulou","year":"2020","journal-title":"Neurochem. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2003.12.001","article-title":"NADPH Oxidase.","volume":"16","author":"Babior","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.compbiomed.2018.09.008","article-title":"Parkinson\u2019s disease: Cause factors, measurable indicators, and early diagnosis.","volume":"102","author":"Bhat","year":"2018","journal-title":"Comput. Biol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","article-title":"Compensatory mechanisms in Parkinson\u2019s disease: Circuits adaptations and role in disease modification.","volume":"298","author":"Blesa","year":"2017","journal-title":"Exp. Neurol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/102602","article-title":"Renin Angiotensin System in Cognitive Function and Dementia.","volume":"2013","author":"Bodiga","year":"2013","journal-title":"Asian J. Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/glia.22595","article-title":"Microglial TNF-\u03b1 mediates enhancement of dopaminergic degeneration by brain angiotensin.","volume":"62","author":"Borrajo","year":"2014","journal-title":"Glia"},{"key":"B9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1476-5381.1996.tb15418.x","article-title":"Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.","volume":"118","author":"Brown","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030551","article-title":"Parkinson\u2019s Disease: From Pathogenesis to Pharmacogenomics.","volume":"18","author":"Cascabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205208","article-title":"Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson\u2019s Disease Models.","volume":"20","author":"Cho","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1007\/s12035-017-0805-y","article-title":"Paracrine and Intracrine Angiotensin 1-7\/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans.","volume":"55","author":"Costa-Besada","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","article-title":"Parkinson\u2019s disease: Autoimmunity and neuroinflammation.","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lpm.2017.01.001","article-title":"Epidemiology, environmental risk factors and genetics of Parkinson\u2019s disease.","volume":"46","author":"Delamarre","year":"2017","journal-title":"Presse M\u00e9dicale"},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control.","volume":"169","author":"Delerive","year":"2001","journal-title":"J. Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28216","article-title":"Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson\u2019s Disease.","volume":"35","author":"Delva","year":"2020","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuropharm.2013.07.016","article-title":"Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson\u2019s disease treated with L-DOPA.","volume":"76","author":"Dominguez-Meijide","year":"2014","journal-title":"Neuropharmacology"},{"key":"B18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1476-5381.2010.00882.x","article-title":"Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson\u2019s disease.","volume":"161","author":"Duty","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00165730","article-title":"DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum.","volume":"345","author":"Dwoskin","year":"1992","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","article-title":"Epidemiology of Parkinson\u2019s disease.","volume":"172","author":"Elbaz","year":"2016","journal-title":"Rev. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias.","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/mutage\/ges033","article-title":"Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4.","volume":"27","author":"Fazeli","year":"2012","journal-title":"Mutagenesis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuron.2018.07.028","article-title":"A cortical pathogenic theory of Parkinson\u2019s Disease.","volume":"99","author":"Foffani","year":"2018","journal-title":"Neuron"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00017","article-title":"Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer\u2019s Disease?","volume":"2","author":"Gallo-Payet","year":"2011","journal-title":"Front. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121551","article-title":"Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular-Subventricular Zone.","volume":"8","author":"Garcia-Garrote","year":"2019","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.expneurol.2013.10.013","article-title":"Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells.","volume":"250","author":"Garrido-Gil","year":"2013","journal-title":"Exp. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00429-016-1357-z","article-title":"Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells.","volume":"222","author":"Garrido-Gil","year":"2017","journal-title":"Brain Struct. Funct."},{"key":"B28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1471-4159.2003.01995.x","article-title":"P2X7 nucleotide receptor activation enhances IFN gamma-induced type II nitric oxide synthase activity in BV-2 microglial cells.","volume":"87","author":"Gendron","year":"2003","journal-title":"J. Neurochem."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316666750","article-title":"Renin-angiotensin system gene expression and neurodegenerative diseases.","volume":"17","author":"Goldstein","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1002\/mds.22020","article-title":"Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.","volume":"23","author":"Grace","year":"2008","journal-title":"Rev. Mov. Disord."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-1","article-title":"Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.","volume":"2","author":"Grammatopoulos","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1152\/physiol.00002.2008","article-title":"An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy.","volume":"23","author":"Grobe","year":"2008","journal-title":"Physiology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/351758","article-title":"The Angiotensin II Type 2 Receptor in Brain Functions: An Update.","volume":"2012","author":"Guimond","year":"2012","journal-title":"Int. J. Hypertens"},{"key":"B34","first-page":"91","article-title":"Angiotensin II\u2013receptor subtypes characterization and pathophysiological implications.","volume":"34","author":"Gulati","year":"1996","journal-title":"Ind. J. Exp. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4149\/endo_2013_01_39","article-title":"Renin-angiotensin system: upgrade of recent knowledge and perspectives.","volume":"47","author":"Herichova","year":"2013","journal-title":"Endocr. Regul."},{"key":"B36","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1476-5381.2010.01167.x","article-title":"Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.","volume":"163","author":"Horiuchi","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030876","article-title":"Within the Brain: The Renin Angiotensin System.","volume":"19","author":"Jackson","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1046\/j.1471-4159.1997.68031304.x","article-title":"Angiotensin-converting enzyme modulates dopamine turnover in the striatum.","volume":"68","author":"Jenkins","year":"1997","journal-title":"J. Neurochem."},{"key":"B39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","article-title":"The inflammatory response in the MPTP model of Parkinson\u2019s disease is mediated by brain angiotensin: relevance to progression of the disease.","volume":"109","author":"Joglar","year":"2009","journal-title":"J. Neurochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.regpep.2007.03.006","article-title":"Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges.","volume":"143","author":"Karamyan","year":"2007","journal-title":"Regul. Pept."},{"key":"B41","doi-asserted-by":"publisher","first-page":"F1110","DOI":"10.1152\/ajprenal.90336.2008","article-title":"Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells.","volume":"295","author":"Khan","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2014.00067","article-title":"Brain renin-angiotensin system and dopaminergic cell vulnerability.","volume":"8","author":"Labandeira-Garc\u00eda","year":"2014","journal-title":"Front. Neuroanat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/mds.25614","article-title":"Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson\u2019s disease.","volume":"28","author":"Labandeira-Garcia","year":"2013","journal-title":"Mov. Disord."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00129","article-title":"Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.","volume":"9","author":"Labandeira-Garcia","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101919","article-title":"The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons.","volume":"8","author":"Labandeira-Garcia","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"22729","DOI":"10.1074\/jbc.271.37.22729","article-title":"Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors.","volume":"271","author":"Laflamme","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease Modification in Parkinson\u2019s Disease: Current Approaches, Challenges, and Future Considerations.","volume":"3","author":"Lang","year":"2018","journal-title":"J. Mov. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","article-title":"Epidemiology of Parkinson Disease.","volume":"34","author":"Lee","year":"2016","journal-title":"Neurol. Clin."},{"key":"B49","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2011040344","article-title":"Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation.","volume":"23","author":"Li","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments.","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"B51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0303-7207(96)03873-7","article-title":"The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells.","volume":"122","author":"Meffert","year":"1996","journal-title":"Mol. Cell Endocrinol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-8993(93)90902-y","article-title":"Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats.","volume":"613","author":"Mendelsohn","year":"1993","journal-title":"Brain Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.neuropharm.2010.01.009","article-title":"Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum.","volume":"58","author":"Mertens","year":"2010","journal-title":"Neuropharmacology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"B55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/01.HYP.0000229648.67883.f9","article-title":"Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.","volume":"48","author":"Mogi","year":"2006","journal-title":"Hypertension"},{"key":"B56","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.expneurol.2014.08.019","article-title":"Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson\u2019s disease. Involvement of vascular endothelial growth factor and interleukin-1\u03b2.","volume":"261","author":"Mu\u00f1oz","year":"2014","journal-title":"Exp. Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","article-title":"Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson\u2019s Disease.","volume":"42","author":"Nguyen","year":"2019","journal-title":"Trends Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.1074\/jbc.M403880200","article-title":"Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP.","volume":"279","author":"Nouet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease.","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02037-z","article-title":"Angiotensin II type 1\/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia.","volume":"7","author":"Oliveira","year":"2017","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1517\/14656566.2014.903924","article-title":"Two new adenosine receptor antagonists for the treatment of Parkinson\u2019s disease: istradefylline versus tozadenant.","volume":"15","author":"Perez-Lloret","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease.","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00109-008-0331-5","article-title":"Brain renin angiotensin in disease.","volume":"86","author":"Phillips","year":"2008","journal-title":"J. Mol. Med."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrn.2017.25","article-title":"The two-century journey of Parkinson disease research.","volume":"18","author":"Przedborski","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1074\/jbc.M307657200","article-title":"NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia.","volume":"279","author":"Qin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/0006-8993(81)90735-6","article-title":"Immunoreactivity for angiotensin II-like peptide in the human brain.","volume":"205","author":"Quinlan","year":"1981","journal-title":"Brain Res."},{"key":"B68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease.","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N Z. J. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"B70","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1460-9568.2004.03621.x","article-title":"Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors.","volume":"20","author":"Rodriguez-Pallares","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","article-title":"Proinflammatory actions of angiotensins.","volume":"10","author":"Ruiz-Ortega","year":"2001","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.pnpbp.2007.04.002","article-title":"Renin-angiotensin-system gene polymorphisms and depression.","volume":"31","author":"Saab","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10571-005-4011-5","article-title":"Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities.","volume":"25","author":"Saavedra","year":"2005","journal-title":"Cell Mol. Neurobiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10571-011-9754-6","article-title":"Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders.","volume":"32","author":"Saavedra","year":"2012","journal-title":"Cell Mol. Neurobiol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.25.1_supplement.822.3","article-title":"Losartan binding to angiotensin AT1 receptors confers allosteric modification of dopamine D1 receptors.","volume":"25","author":"Scott","year":"2011","journal-title":"FASEB J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Medie"},{"key":"B78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0169-328x(97)00298-2","article-title":"Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor.","volume":"53","author":"Stroth","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/1470320313494432","article-title":"The angiotensin-converting enzyme (ACE) I\/D polymorphism in Parkinson\u2019s disease.","volume":"16","author":"Su","year":"2015","journal-title":"JRAAS"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson\u2019s disease.","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/01.cir.102.15.1834","article-title":"Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells.","volume":"102","author":"Takeda","year":"2000","journal-title":"Circulation"},{"key":"B82","first-page":"I40","article-title":"Brain angiotensin: pathways and pharmacology.","volume":"77","author":"Unger","year":"1988","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/NEN.0b013e3181fa0308","article-title":"Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death.","volume":"69","author":"Valenzuela","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.327","article-title":"Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration.","volume":"7","author":"Valenzuela","year":"2016","journal-title":"Cell Death Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.439","article-title":"The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system.","volume":"8","author":"Villar-Cheda","year":"2017","journal-title":"Cell Death Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.neurobiolaging.2014.01.017","article-title":"Aging-related dysregulation of dopamine and angiotensin receptor interaction.","volume":"35","author":"Villar-Cheda","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B88","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1460-9568.2010.07448.x","article-title":"Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson\u2019s disease.","volume":"32","author":"Villar-Cheda","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-006-0190-8","article-title":"The CNS renin-angiotensin system.","volume":"326","author":"von Bohlen und Halbach","year":"2006","journal-title":"Cell Tissue Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/mds.27823","article-title":"Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?","volume":"34","author":"Wong","year":"2019","journal-title":"Mov. Disord."},{"key":"B91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0149-7634(94)90034-5","article-title":"Brain angiotensin receptor subtypes in the control of physiological and behavioral responses.","volume":"18","author":"Wright","year":"1994","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.","volume":"465","author":"Wright","year":"2013","journal-title":"Pflugers Arch."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0189-z","article-title":"Loss of angiotensin II receptor expression in dopamine neurons in Parkinson\u2019s disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation.","volume":"3","author":"Zawada","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184391","article-title":"Roles of Glutamate Receptors in Parkinson\u2019s Disease.","volume":"20","author":"Zhang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"crossref","first-page":"11395","DOI":"10.1111\/j.1471-4159.2005.03275.x","article-title":"Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation.","volume":"94","author":"Zhao","year":"2005","journal-title":"J. Neurochem."}],"container-title":["Frontiers in Synaptic Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnsyn.2021.638519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T09:42:29Z","timestamp":1619084549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnsyn.2021.638519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":95,"alternative-id":["10.3389\/fnsyn.2021.638519"],"URL":"https:\/\/doi.org\/10.3389\/fnsyn.2021.638519","relation":{},"ISSN":["1663-3563"],"issn-type":[{"value":"1663-3563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"638519"}}